FOURTH WAIVER TO AGREEMENT AND PLAN OF MERGERWaiver to Agreement and Plan of Merger • October 18th, 2024 • Revance Therapeutics, Inc. • Pharmaceutical preparations
This FOURTH WAIVER TO AGREEMENT AND PLAN OF MERGER (this “Waiver”), dated October 18, 2024, is made by and among Crown Laboratories, Inc., a Delaware corporation (“Parent”), Reba Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Revance Therapeutics, Inc., a Delaware corporation (the ”Company”), and waives certain provisions (as set forth herein) of that certain Agreement and Plan of Merger, dated August 11, 2024 (as the same may be amended, modified or restated in accordance with the terms thereof, the “Merger Agreement”), by and among Parent, Merger Sub and the Company. Capitalized terms used herein but not otherwise defined shall have the meanings ascribed to them in the Merger Agreement.
